HZNP—FDA approves Tepezza for Thyroid Eye Disease—a rare disease: https://finance.yahoo.com/news/fda-approves-tepezzatm-teprotumumab-trbw-200400211.html This is the drug HZNP picked up in its 2017 buyout of River Vision for $145M (#msg-131172440).